Novartis International AG http://www.novartis.com Novartis DEB025 data showed viral clearance as early as six weeks and potential for interferon-free therapy in hepatitis C patients 2011-11-05T15:00:00 CET http://www.novartis.com/newsroom/media-releases/en/2011/1561233.shtml Novartis delivers strong financial results and four major approvals in second quarter of 2011 2011-07-19T07:00:00 CET http://www.novartis.com/newsroom/media-releases/en/2011/1531819.shtml Novartis application for expanded Menveo® indication from 2 months of age accepted for review by FDA 2011-06-16T07:15:00 CET http://www.novartis.com/newsroom/media-releases/en/2011/1523779.shtml Novartis candidate vaccine Bexsero® shows significant potential in providing broad coverage against meningococcal serogroup B infections 2011-06-09T07:15:00 CET http://www.novartis.com/newsroom/media-releases/en/2011/1522283.shtml FDA approves the Novartis quadrivalent meningococcal conjugate vaccine, Menveo®, for use in children from 2 years of age 2011-01-31T07:15:00 CET http://www.novartis.com/newsroom/media-releases/en/2011/1483545.shtml Novartis submits Bexsero®, a multi-component meningococcal B vaccine, for regulatory review in Europe 2010-12-23T07:15:00 CET http://www.novartis.com/newsroom/media-releases/en/2010/1475256.shtml New data show potential for Novartis Meningitis B vaccine (4CMenB) candidate to cover majority of diverse meningococcal serogroup B strains 2010-11-04T07:15:00 CET http://www.novartis.com/newsroom/media-releases/en/2010/1458801.shtml Phase III data show that Novartis meningococcal vaccine Menveo® demonstrated robust immunogenicity in infants 2010-10-25T07:15:00 CET http://www.novartis.com/newsroom/media-releases/en/2010/1454719.shtml Novartis Phase III study indicates MF59® adjuvanted influenza vaccine, Fluad®, is 75 percent more efficacious than studied non-adjuvanted vaccines in young children 2010-10-22T07:15:00 CET http://www.novartis.com/newsroom/media-releases/en/2010/1454259.shtml Novartis delivers excellent performance in third quarter: recently launched products generate 20%* of sales; Gilenya approved; Alcon consolidated 2010-10-21T07:00:00 CET http://www.novartis.com/newsroom/media-releases/en/2010/1453762.shtml Novartis obtains CHMP positive opinion for its investigational pre-pandemic influenza vaccine Aflunov® to help protect against (H5N1) avian influenza 2010-09-24T17:38:00 CET http://www.novartis.com/newsroom/media-releases/en/2010/1446813.shtml Novartis Phase III study shows meningococcal B vaccine candidate could be first to provide broad coverage against deadly disease 2010-09-12T17:00:00 CET http://www.novartis.com/newsroom/media-releases/en/2010/1443940.shtml Novartis delivers strong financial performance in second quarter, underpinned by increased momentum in innovation 2010-07-15T07:00:00 CET http://www.novartis.com/newsroom/media-releases/en/2010/1431809.shtml Novartis healthcare portfolio generates strong growth in first quarter of 2010, progress on delivering innovation, growth and productivity 2010-04-20T07:00:00 CET http://www.novartis.com/newsroom/media-releases/en/2010/1405499.shtml Novartis receives approval in the European Union for Menveo®, first quadrivalent conjugate vaccine in the EU to help prevent meningococcal disease 2010-03-18T07:15:00 CET http://www.novartis.com/newsroom/media-releases/en/2010/1395085.shtml Novartis receives FDA approval of Menveo®, a vaccine to prevent meningococcal disease 2010-02-22T07:05:00 CET http://www.novartis.com/newsroom/media-releases/en/2010/1386845.shtml Novartis erzielt im zweiten Quartal 2011 starke Finanzergebnisse und erreicht vier wichtige Zulassungen 2011-07-19T07:00:00+01:00 http://www.novartis.com/newsroom/media-releases/de/2011/1531821.shtml Novartis erzielt im dritten Quartal eine hervorragende Performance: Die jüngsten Produkte steuern 20%* zum Umsatz bei; Gilenya wird zugelassen; Alcon wird konsolidiert 2010-10-21T07:00:00+01:00 http://www.novartis.com/newsroom/media-releases/de/2010/1453748.shtml